Targeting Unmet Medical Needs in NCFB with AVTX-002: Avalo's lead program, AVTX-002 (quisatimod), is an anti-IL-1β monoclonal antibody focused on Non-Cystic Fibrosis Bronchiectasis (NCFB), a chronic and progressive lung disease with significant unmet medical needs and limited approved treatment options.

Differentiated Mechanism of Action for AVTX-002: AVTX-002 specifically targets and inhibits Interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine, offering a targeted approach to reduce inflammation and potentially slow disease progression in NCFB.

Strategic Pipeline Focus and Prioritization: The company has undergone a significant strategic re-prioritization, divesting non-core assets and concentrating resources on the development of AVTX-002 for NCFB, enhancing operational efficiency and extending the cash runway.